BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 21765048)

  • 1. Identifying factors that impact survival among women with inflammatory breast cancer.
    Dawood S; Ueno NT; Valero V; Woodward WA; Buchholz TA; Hortobagyi GN; Gonzalez-Angulo AM; Cristofanilli M
    Ann Oncol; 2012 Apr; 23(4):870-5. PubMed ID: 21765048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
    Jiao D; Zhang J; Zhu J; Guo X; Yang Y; Xiao H; Liu Z
    BMC Cancer; 2021 Feb; 21(1):138. PubMed ID: 33549037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study.
    Dawood S; Ueno NT; Valero V; Woodward WA; Buchholz TA; Hortobagyi GN; Gonzalez-Angulo AM; Cristofanilli M
    Cancer; 2011 May; 117(9):1819-26. PubMed ID: 21509759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
    Fouad TM; Kogawa T; Liu DD; Shen Y; Masuda H; El-Zein R; Woodward WA; Chavez-MacGregor M; Alvarez RH; Arun B; Lucci A; Krishnamurthy S; Babiera G; Buchholz TA; Valero V; Ueno NT
    Breast Cancer Res Treat; 2015 Jul; 152(2):407-16. PubMed ID: 26017070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and Validation of Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Nonmetastatic Inflammatory Breast Cancer Patients Receiving Tri-Modality Therapy: A Population-Based Study.
    Huang Q; Xu TY; Wu ZY
    Med Sci Monit; 2019 Dec; 25():9167-9178. PubMed ID: 31789307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.
    Schinkel JK; Zahm SH; Jatoi I; McGlynn KA; Gallagher C; Schairer C; Shriver CD; Zhu K
    Cancer Causes Control; 2014 Aug; 25(8):959-68. PubMed ID: 24839049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
    Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of women with inflammatory breast cancer: a large population-based study.
    Dawood S; Lei X; Dent R; Gupta S; Sirohi B; Cortes J; Cristofanilli M; Buchholz T; Gonzalez-Angulo AM
    Ann Oncol; 2014 Jun; 25(6):1143-51. PubMed ID: 24669011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database.
    Liu YL; Wang DW; Yang ZC; Ma R; Li Z; Suo W; Zhao Z; Li ZW
    Breast Cancer Res Treat; 2019 Nov; 178(2):379-388. PubMed ID: 31414242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of CNS metastases and survival in patients with inflammatory breast cancer.
    Uemura MI; French JT; Hess KR; Liu D; Raghav K; Hortobagyi GN; Arun BK; Valero V; Ueno NT; Alvarez RH; Woodward WA; Debeb BG; Moulder SL; Lim B; Tripathy D; Ibrahim NK
    Cancer; 2018 Jun; 124(11):2299-2305. PubMed ID: 29579338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
    Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
    Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of and survival following brain metastases among women with inflammatory breast cancer.
    Dawood S; Ueno NT; Valero V; Andreopoulou E; Hsu L; Lara J; Woodward W; Buchholz TA; Hortobagyi GN; Cristofanilli M
    Ann Oncol; 2010 Dec; 21(12):2348-2355. PubMed ID: 20439340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.
    Schlichting JA; Soliman AS; Schairer C; Schottenfeld D; Merajver SD
    Breast Cancer Res Treat; 2012 Aug; 134(3):1257-68. PubMed ID: 22733221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
    van Uden DJP; van Maaren MC; Bult P; Strobbe LJA; van der Hoeven JJM; Blanken-Peeters CFJM; Siesling S; de Wilt JHW
    Breast Cancer Res Treat; 2019 Jul; 176(1):217-226. PubMed ID: 30972613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
    Diessner J; Van Ewijk R; Weiss CR; Janni W; Wischnewsky MB; Kreienberg R; Hancke K; Blettner M; Wöckel A; Schwentner L
    Arch Gynecol Obstet; 2015 Sep; 292(3):655-64. PubMed ID: 25814296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
    Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
    Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.
    Weiss A; Menen RS; Lin HY; Shen Y; Rosso KJ; Shaitelman S; Woodward W; Valero V; Ueno NT; Bedrosian I; Babiera G
    Breast Cancer Res Treat; 2018 Jun; 169(3):615-623. PubMed ID: 29460033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and validation of a nomogram to predict overall survival in patients with inflammatory breast cancer.
    Diao JD; Ma LX; Sun MY; Wu CJ; Wang LJ; Liu YL; Yang YJ
    Cancer Med; 2019 Sep; 8(12):5600-5608. PubMed ID: 31407527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
    van Uden DJP; van Maaren MC; Strobbe LJA; Bult P; van der Hoeven JJ; Siesling S; de Wilt JHW; Blanken-Peeters CFJM
    Breast Cancer Res; 2019 Oct; 21(1):113. PubMed ID: 31623649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.